Skip links

EMDA vs BCG for bladder cancer treatment

JS Medical will be exhibiting the EMDA® drug delivery system at BAUS Brighton.

Following the publication of the latest trial results from the Urology group at Guy’s & St Thomas’ NHS Foundation Trust, JS Medical will be demonstrating the EMDA® treatment package at the BAUS Section of Oncology Meeting in Brighton from 21 to 22 November 2019.

The study cites: “This is twice the efficacy quoted for intravesical BCG alone and adds further weight to the adoption of this sequential regimen in bladder preservation for HR-NMIBC.”1

EMDA® has been shown to be a useful alternative strategy in bladder preservation for HR-NMIBC patients who fail BCG. In addition, BAUS, EAU and NICE have suggested that hospitals switch to offering our EMDA®+Mitomycin-C treatment due to the worldwide shortage of BCG.

Iontophoresis process during EMDA+MMC treatment

MDA®+Mitomycin-C (MMC) has been proven to significantly prolong the disease-free interval of non-muscle invasive bladder cancer (NMIBC) patients. This treatment is pre-TURBT and has also been shown to reduce the risk of recurrence in high and intermediate-risk NMIBC patients.

JS Medical has taken active steps during 2019 to ensure continuity of supply, investing substantially in stock to reassure our client hospitals that EMDA® consumables will continue to be delivered as normal within 48 hours of ordering.

Clinicians interested in discussing the benefits of EMDA treatment for their patients or in arranging a personal meeting at Brighton, should contact Murat Celebi, Clinical Marketing Director, on +44 (0)1234-888955 or by email via

1 Event Abstract: Front. Oncol. Conference Abstract: Bladder Cancer Translational Research Meeting. doi: 10.3389/conf.fonc.2019.01.00015